Mylan Found to Have Infringed Medicines Co.’s Patent

Updated on

The Medicines Co. won a U.S. court ruling that drugmaker Mylan Inc. infringed a patent for its blood-clot-inhibiting drug Angiomax, which accounted for almost 90 percent of Medicines Co.’s revenue last year.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.